Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Nov 2022
Historique:
received: 01 07 2022
revised: 30 09 2022
accepted: 01 10 2022
pubmed: 10 10 2022
medline: 16 11 2022
entrez: 9 10 2022
Statut: ppublish

Résumé

Bacterial nanocellulose has been widely investigated for wound healing applications, mainly due to its moisturizing capabilities and biocompatibility. Even though the topical therapy of nail diseases could benefit from these properties, this application has not yet been investigated. Therefore, actively hydrating nail patches based on bacterial nanocellulose were developed to improve the delivery of ciclopirox olamine and Boswellia serrata extract through the nail plate. The nanocellulose matrix was used to enable the application of hydration enhancing solutions based on glycerol and urea as a mechanically stable patch. While the favorable mechanical characteristics of the material remained unchanged, an increase of the incorporated glycerol concentration enhanced the transparency and wetting capacity of the patches. A biphasic drug release from the patches could be observed for drug and extract with a faster release for the hydrophilic ciclopirox olamine. High glycerol concentrations correlated with increased cumulative release and permeation through keratin films for drug and extract, demonstrating the hydration driven permeation enhancement. Patches containing ciclopirox olamine showed strong antimycotic effects against relevant pathogens for onychomycosis. The present finding proposed the combination of bacterial nanocellulose with glycerol, urea and different drug as a promising platform for the local treatment of nail diseases.

Identifiants

pubmed: 36209980
pii: S0378-5173(22)00822-5
doi: 10.1016/j.ijpharm.2022.122267
pii:
doi:

Substances chimiques

Ciclopirox 19W019ZDRJ
Antifungal Agents 0
Glycerol PDC6A3C0OX
Pyridones 0
Excipients 0
Urea 8W8T17847W
Plant Extracts 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122267

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tom Bellmann (T)

Division of Pharmaceutical Technology and Biopharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Cauerstraße 4, 91058 Erlangen, Germany. Electronic address: tom.bellmann@fau.de.

Ruth Luber (R)

Division of Pharmaceutical Technology and Biopharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Cauerstraße 4, 91058 Erlangen, Germany. Electronic address: ruth.luber@gmail.com.

Lisa Kischio (L)

Pharmaceutical Technology and Biopharmacy, Friedrich-Schiller-University Jena, Lessingstraße 8, 07743 Jena, Germany. Electronic address: kischiolisa@gmail.com.

Berit Karl (B)

Pharmaceutical Technology and Biopharmacy, Friedrich-Schiller-University Jena, Lessingstraße 8, 07743 Jena, Germany. Electronic address: beritkarl@gmx.de.

Yvette Pötzinger (Y)

Pharmaceutical Technology and Biopharmacy, Friedrich-Schiller-University Jena, Lessingstraße 8, 07743 Jena, Germany. Electronic address: yvette.poetzinger@gmail.com.

Uwe Beekmann (U)

JeNaCell GmbH - An Evonik Company, Göschwitzer Straße 22, 07745 Jena, Germany. Electronic address: uwe.beekmann@evonik.com.

Dana Kralisch (D)

JeNaCell GmbH - An Evonik Company, Göschwitzer Straße 22, 07745 Jena, Germany; Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, 07743 Jena, Germany. Electronic address: dana.kralisch@evonik.com.

Cornelia Wiegand (C)

University Medical Center Jena, Department of Dermatology, Erfurter Straße 35, 07740 Jena, Germany. Electronic address: c.wiegand@med.uni-jena.de.

Dagmar Fischer (D)

Division of Pharmaceutical Technology and Biopharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Cauerstraße 4, 91058 Erlangen, Germany; Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, 07743 Jena, Germany. Electronic address: dagmar.fischer@fau.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH